FindMyKOL
Clinical trialNCT04794699Active, not recruitingPhase 1Interventional

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

SponsorIDEAYA BiosciencesEnrollment169Solid Tumor
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

37 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • the Kinghorn Cancer Centre, St Vincent'S Health Network Sydney

    Darlinghurst, New South Wales, Australia

  • Southern Oncology Clinical Research Unit

    Bedford Park, South Australia, Australia

France
  • Institut Bergonie

    Bordeaux, Bordeaux Cedex, France

  • Institut Claudius Regaud - Iuct-Oncopole

    Toulouse, Cedex 9, France

  • Hôpital Timone

    Marseille, Marseille, France

  • Centre Georges Francois Leclerc

    Dijon, France

  • Centre Eugène Marquis

    Rennes, France

  • Gustave Roussy

    Villejuif, France

Germany
  • Universitaetsklinikum Hamburg-Eppendorf (uke)

    Hamburg, Germany

South Korea
  • National Cancer Center

    Goyang-si, Gyeonggi-do, South Korea

  • Cha University - Bundang Medical Center

    Seongnam-si, Gyeonggi-do, South Korea

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Sevrance Hospital

    Seoul, South Korea

Spain
  • Hospital Universitario 12 de Octubre (h12o)

    Madrid, Spain

  • Next Madrid, Universitary Hospital Quironsalud

    Madrid, Spain

  • Start Madrid-Hm - Centro Integral Oncológico Clara Campal (ciocc)

    Madrid, Spain

  • Instituto Valenciano de Oncología (ivo)

    Valencia, Spain

Taiwan
  • National Cheng Kung University Hospital

    Tainan, Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taipei, Taiwan

United States
  • Honor Health Research Institute

    Scottsdale, Arizona, United States

  • Rockefeller Cancer Institute

    Little Rock, Arkansas, United States

  • City of Hope

    Duarte, California, United States

  • Orlando Health Cancer Institute

    Orlando, Florida, United States

  • Indiana University Health Hospital

    Indianapolis, Indiana, United States

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

  • Columbia University Medical Center - Herbert Irving Pavilion

    New York, New York, United States

  • Weill Cornell Medical College

    New York, New York, United States

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma, United States

  • Lifespan - Brown University

    Providence, Rhode Island, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, United States

  • Md Anderson

    Houston, Texas, United States

  • Next Oncology

    San Antonio, Texas, United States

  • Swedish Cancer Institute

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IDE397Sacituzumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
14 Apr 2021
Primary completion
7 Jan 2027
Completion
4 Feb 2027
Last update posted
9 Apr 2026
Registered enrollment
169
Registry id
NCT04794699
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.